{"id":6664,"date":"2026-10-23T11:18:56","date_gmt":"2026-10-23T02:18:56","guid":{"rendered":"https:\/\/cm-plus.co.jp\/en\/?post_type=column&#038;p=6664"},"modified":"2026-10-23T11:18:56","modified_gmt":"2026-10-23T02:18:56","slug":"2026_1023","status":"publish","type":"column","link":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/","title":{"rendered":"GMP WATCH NEWS &#8211; A Veteran&#8217;s Perspective\uff3b3\uff3d"},"content":{"rendered":"<p><span style=\"font-size: 22px;\"><strong>Paradigm Shifts in Pharmaceutical Quality Systems<br \/>\nA Historical Review and Future Perspectives [Part 3]<\/strong><\/span><\/p>\n<p><img decoding=\"async\" class=\"size-full wp-image-6665 aligncenter\" src=\"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/10\/A-Veterans_3-1.jpg\" alt=\"\" width=\"80%\" height=\"\" srcset=\"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/10\/A-Veterans_3-1.jpg 1000w, https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/10\/A-Veterans_3-1-300x139.jpg 300w, https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/10\/A-Veterans_3-1-768x355.jpg 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><\/p>\n<p><strong><span style=\"font-size: 14pt;\">From QC to the Pharmaceutical Quality System (PQS)<br \/>\n<\/span><\/strong>When GMP was first introduced in 1963, the \u201ctesting\u201d conducted by the QC department played a central role. However, as GMP evolved, there was a dramatic increase in complex tasks beyond testing, such as document control, change control, and deviation management. Consequently, the FDA revised CGMP in 1978, significantly strengthening the authority of the QC department. It clarified the department\u2019s independence from the manufacturing department and its final authority over release decisions, effectively mandating that the QC department also assume the current role of Quality Assurance (QA).<\/p>\n<p>Furthermore, in 1987, the ISO 9000 Series (Quality Management Systems) was established, clearly defining the term \u201cQuality Assurance (QA)\u201d and spreading it worldwide. This marked the point at which QC, responsible for testing, and QA, responsible for ensuring the integrity of the entire system, became clearly distinguished. In 2008, ICH Q10 introduced the concept of a \u201cPharmaceutical Quality System (PQS),\u201d which includes management responsibility. QA was redefined not merely as an on-site monitor, but as a department responsible for quality assurance at the management level.<\/p>\n<p>By the way, the term \u201cQuality Unit (QU)\u201d was first used in ICH Q7, \u201cGuideline on Good Manufacturing Practice for Pharmaceutical Active Substances,\u201d published in 2000, where a QU was defined as an organization responsible for both QC and QA. Furthermore, in the FDA guidance document \u201cQuality System Approach\u201d published in 2006, the traditional regulatory term \u201cQuality Control Unit\u201d was replaced with \u201cQuality Unit.\u201d<\/p>\n<p>Due to the historical evolution of GMP, department names vary widely: some companies have QA functions within their \u201cQC units,\u201d while others have \u201cQA units\u201d that also perform testing; in smaller factories, a single department may handle everything.<\/p>\n<p>Therefore, we have decided to use the term \u201cQU\u201d to refer to the entire organization responsible for quality, and to emphasize that QC and QA are inseparable functions. However, please note that the U.S. CGMP (21 CFR Part 211) still uses the term \u201cQuality Control Unit,\u201d so please be careful not to get confused.<\/p>\n<p>Around the time the concept of process validation was redefined, ICH Q10 introduced the concept of PQS. This was because incidents and supply shortages\u2014which could not be prevented simply by manufacturing according to established procedures and shipping products only after they passed final testing\u2014had occurred, leading to a need for management as a more comprehensive system.<\/p>\n<p>With the introduction of PQS: (1) it became necessary to manage all stages\u2014from development through manufacturing to the end of a product\u2019s marketing\u2014under a consistent quality policy; (2) it was explicitly stated that senior management bears ultimate responsibility for quality issues, which had previously tended to be the responsibility of the manufacturing site; and (3) there was a shift from a passive stance of following rules to an active stance of analyzing data and continuously improving on our own.<\/p>\n<p>While GMP refers to \u201crules for producing good products on tthe manufacturing site, PQS denotes a broader framework\u2014\u201ca system for maintaining and improving quality across the entire company\u201d\u2014and incorporates GMP as part of this system, thereby contributing to pharmaceutical quality assurance.<\/p>\n<hr \/>\n<p><strong>Author<\/strong><\/p>\n<div style=\"display: flex; align-items: flex-start; margin-top: 10px; margin-bottom: 30px;\">\n<div style=\"width: 120px; min-width: 120px; margin-right: 20px; text-align: center;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-2150 size-full\" style=\"margin: 0 auto; display: block;\" src=\"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2024\/05\/photo_nakao.jpg\" alt=\"\" width=\"110\" height=\"150\" \/><\/div>\n<div style=\"flex: 1; min-width: 0; text-align: justify;\"><a href=\"https:\/\/www.gmp-platform.com\/en\/author_detail.html?id=74\" target=\"_blank\" rel=\"noopener\">Akio Nakao, Ph.D.<\/a><br \/>\nNakao started his career in 1976 at Tanabe Seiyaku Co., Ltd. After carrying out research in synthetic organic chemistry and process chemistry (industrialization) at the company, he successively took the positions of quality assurance manager, director and general manager of production, and managing director in charge of management planning. After Tanabe merged with Mitsubishi to become Mitsubishi Tanabe Pharma Corporation, Nakao became Managing Executive Officer and Chief Director of Medicine Manufacturing. Through his experience in dealing with FDA inspections and activities at the Parenteral Drug Association (PDA), Nakao became convinced that GMP is an &#8220;exact science.&#8221;<br \/>\nFinding that his beliefs were reflected in CM Plus Corporation&#8217;s enthusiasm for improving GMP education, Nakao joined CM Plus in 2011 as a Director and be promoted as executive vice-president in 2012. Fellow since July 2017.<\/div>\n<\/div>\n<p><strong style=\"text-align: justify;\">About GMP Platform<\/strong><span style=\"text-align: justify;\"> (<\/span><span style=\"color: #e04040;\"><a style=\"color: #e04040;\" href=\"https:\/\/www.gmp-platform.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.gmp-platform.com\/<\/a><\/span><span style=\"text-align: justify;\">)<\/span><\/p>\n<div style=\"display: flex; align-items: flex-start; margin-top: 10px;\">\n<div style=\"width: 120px; min-width: 120px; margin-right: 20px; text-align: center;\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-6287\" style=\"margin: 0 auto; display: block;\" src=\"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/06\/67a6e7abd7eed66835c60503b99f2499.png\" alt=\"\" width=\"111\" height=\"62\" \/><\/div>\n<div style=\"flex: 1; min-width: 0; text-align: justify;\">GMP Platform is a free GMP-related information portal established in 2012 and operated by CM Plus Corporation. Built on CM Plus\u2019s founding principle of addressing quality-related issues in life science facilities, the site provides practical, expert-led information for life science manufacturing professionals. With more than 26,000 registered users, GMP Platform introduces the latest GMP-related regulations and trends in Japan, the United States, Europe, and other regions, along with translated and explanatory articles on guidelines, technical articles, seminars, e-learning programs, and books. It is widely used by professionals involved in GMP compliance, quality assurance, and the development of effective quality systems.Please use Google Translate or similar translation tools to read more articles originally published in Japanese.<br \/>\n*If you are using Google Chrome, right-click and select &#8220;Google Translate&#8221; on the article.<\/div>\n<\/div>\n","protected":false},"featured_media":6469,"template":"","columncat":[61],"columntag":[],"keywords":[11],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GMP WATCH NEWS - A Veteran&#039;s Perspective\uff3b3\uff3d\uff5cCM Plus<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GMP WATCH NEWS - A Veteran&#039;s Perspective\uff3b3\uff3d\uff5cCM Plus\" \/>\n<meta property=\"og:description\" content=\"Paradigm Shifts in Pharmaceutical Quality Systems A Historical Review and Future Perspectives [Part 3] From QC to the Pharmaceutical Quality System (PQS) When GMP was first introduced in 1963, the \u201ctesting\u201d conducted by the QC department played a central role. However, as GMP evolved, there was a dramatic increase in complex tasks beyond testing, such as document control, change control, and deviation management. Consequently, the FDA revised CGMP in 1978, significantly strengthening the authority of the QC department. It clarified the department\u2019s independence from the manufacturing department and its final authority over release decisions, effectively mandating that the QC department also assume the current role of Quality Assurance (QA). Furthermore, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/\" \/>\n<meta property=\"og:site_name\" content=\"CM Plus\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2024\/05\/ogp.png\" \/>\n\t<meta property=\"og:image:width\" content=\"928\" \/>\n\t<meta property=\"og:image:height\" content=\"458\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/\",\"url\":\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/\",\"name\":\"GMP WATCH NEWS - A Veteran's Perspective\uff3b3\uff3d | CM Plus\",\"isPartOf\":{\"@id\":\"https:\/\/cm-plus.co.jp\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/08\/GMPP_cat_Others_127.jpg\",\"datePublished\":\"2026-10-23T02:18:56+00:00\",\"dateModified\":\"2026-10-23T02:18:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#primaryimage\",\"url\":\"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/08\/GMPP_cat_Others_127.jpg\",\"contentUrl\":\"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/08\/GMPP_cat_Others_127.jpg\",\"width\":928,\"height\":458},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u30db\u30fc\u30e0\",\"item\":\"https:\/\/cm-plus.co.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Column\",\"item\":\"https:\/\/cm-plus.co.jp\/en\/column\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"GMP WATCH NEWS &#8211; A Veteran&#8217;s Perspective\uff3b3\uff3d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cm-plus.co.jp\/en\/#website\",\"url\":\"https:\/\/cm-plus.co.jp\/en\/\",\"name\":\"CM Plus\",\"description\":\"Your Partner in Facility Construction, Quality Assurance, and GMP Education\/Training\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cm-plus.co.jp\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GMP WATCH NEWS - A Veteran's Perspective\uff3b3\uff3d\uff5cCM Plus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/","og_locale":"en_US","og_type":"article","og_title":"GMP WATCH NEWS - A Veteran's Perspective\uff3b3\uff3d\uff5cCM Plus","og_description":"Paradigm Shifts in Pharmaceutical Quality Systems A Historical Review and Future Perspectives [Part 3] From QC to the Pharmaceutical Quality System (PQS) When GMP was first introduced in 1963, the \u201ctesting\u201d conducted by the QC department played a central role. However, as GMP evolved, there was a dramatic increase in complex tasks beyond testing, such as document control, change control, and deviation management. Consequently, the FDA revised CGMP in 1978, significantly strengthening the authority of the QC department. It clarified the department\u2019s independence from the manufacturing department and its final authority over release decisions, effectively mandating that the QC department also assume the current role of Quality Assurance (QA). Furthermore, [&hellip;]","og_url":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/","og_site_name":"CM Plus","og_image":[{"width":928,"height":458,"url":"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2024\/05\/ogp.png","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/","url":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/","name":"GMP WATCH NEWS - A Veteran's Perspective\uff3b3\uff3d | CM Plus","isPartOf":{"@id":"https:\/\/cm-plus.co.jp\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#primaryimage"},"image":{"@id":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#primaryimage"},"thumbnailUrl":"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/08\/GMPP_cat_Others_127.jpg","datePublished":"2026-10-23T02:18:56+00:00","dateModified":"2026-10-23T02:18:56+00:00","breadcrumb":{"@id":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#primaryimage","url":"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/08\/GMPP_cat_Others_127.jpg","contentUrl":"https:\/\/cm-plus.co.jp\/en\/wp-content\/uploads\/2026\/08\/GMPP_cat_Others_127.jpg","width":928,"height":458},{"@type":"BreadcrumbList","@id":"https:\/\/cm-plus.co.jp\/en\/column\/gmp\/2026_1023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u30db\u30fc\u30e0","item":"https:\/\/cm-plus.co.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Column","item":"https:\/\/cm-plus.co.jp\/en\/column\/"},{"@type":"ListItem","position":3,"name":"GMP WATCH NEWS &#8211; A Veteran&#8217;s Perspective\uff3b3\uff3d"}]},{"@type":"WebSite","@id":"https:\/\/cm-plus.co.jp\/en\/#website","url":"https:\/\/cm-plus.co.jp\/en\/","name":"CM Plus","description":"Your Partner in Facility Construction, Quality Assurance, and GMP Education\/Training","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cm-plus.co.jp\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/column\/6664"}],"collection":[{"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/column"}],"about":[{"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/types\/column"}],"version-history":[{"count":4,"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/column\/6664\/revisions"}],"predecessor-version":[{"id":6669,"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/column\/6664\/revisions\/6669"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/media\/6469"}],"wp:attachment":[{"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/media?parent=6664"}],"wp:term":[{"taxonomy":"columncat","embeddable":true,"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/columncat?post=6664"},{"taxonomy":"columntag","embeddable":true,"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/columntag?post=6664"},{"taxonomy":"keywords","embeddable":true,"href":"https:\/\/cm-plus.co.jp\/en\/wp-json\/wp\/v2\/keywords?post=6664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}